New drugs in Brazil: do they meet Brazilian public health needs?
about
The evolution of Reference Drug Lists and Clinical Practice Guidelines in the public health system of a middle-income countryBiotechnology of polyketides: new breath of life for the novel antibiotic genetic pathways discovery through metagenomicsThe fuzzy line between needs, coverage, and excess in the Mexican Formulary List: an example of qualitative market width analysis.Windows of opportunities and technological innovation in the Brazilian pharmaceutical industry.The production and R&D structure of the Brazilian pharmaceutical industry: the role of public procurement and public drug production.
P2860
New drugs in Brazil: do they meet Brazilian public health needs?
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
New drugs in Brazil: do they meet Brazilian public health needs?
@en
New drugs in Brazil: do they meet Brazilian public health needs?
@nl
type
label
New drugs in Brazil: do they meet Brazilian public health needs?
@en
New drugs in Brazil: do they meet Brazilian public health needs?
@nl
prefLabel
New drugs in Brazil: do they meet Brazilian public health needs?
@en
New drugs in Brazil: do they meet Brazilian public health needs?
@nl
P2093
P1476
New drugs in Brazil: do they meet Brazilian public health needs?
@en
P2093
Carlos Cezar Flores Vidotti
Lia Lusitana Cardozo de Castro
Simone Saad Calil
P356
10.1590/S1020-49892008000700005
P577
2008-07-01T00:00:00Z